Literature DB >> 15950099

Whole-body MR imaging of bone marrow.

G P Schmidt1, S O Schoenberg, M F Reiser, A Baur-Melnyk.   

Abstract

In clinical routine, multimodality algorithms, including X-ray, computed tomography, scintigraphy and MRI, are used in case of suspected bone marrow malignancy. Skeletal scintigraphy is widely used to asses metastatic disease to the bone, CT is the technique of choice to assess criteria of osseous destruction and bone stability. MRI is the only imaging technique that allows direct visualization of bone marrow and its components with high spatial resolution. The combination of unenhanced T1-weighted-spin echo- and turbo-STIR-sequences have shown to be most useful for the detection of bone marrow abnormalities and are able to discriminate benign from malignant bone marrow changes. Originally, whole-body MRI bone marrow screening was performed in sequential scanning techniques of five body levels with time consuming coil rearrangement and repositioning of the patient. The introduction of a rolling platform mounted on top of a conventional MRI examination table facilitated whole-body MR imaging and, with the use of fast gradient echo, T1-weighted and STIR-imaging techniques, for the first time allowed whole-body imaging within less than one hour. With the development of parallel imaging techniques (PAT) in combination with global matrix coil concepts, acquisition time could be reduced substantially without compromises in spatial resolution, enabling the implementation of more complex and flexible examination protocols. Whole-body MRI represents a new alternative to the stepwise multimodality concept for the detection of metastatic disease, multiple myeloma and lymphoma of the bone with high diagnostic accuracy.

Entities:  

Mesh:

Year:  2005        PMID: 15950099     DOI: 10.1016/j.ejrad.2005.01.019

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  20 in total

1.  [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging].

Authors:  C Plathow; M Walz; M P Lichy; P Aschoff; C Pfannenberg; H Bock; S M Eschmann; C D Claussen; H P Schlemmer
Journal:  Radiologe       Date:  2008-04       Impact factor: 0.635

Review 2.  The evolving role of MRI in oncohaematological disorders.

Authors:  O Tamburrini; M A Cova; D Console; P Martingano
Journal:  Radiol Med       Date:  2007-07-24       Impact factor: 3.469

3.  Application of high-resolution 1H MAS NMR spectroscopy to the analysis of intact bones from mice exposed to gamma radiation.

Authors:  Qibin Zhang; Jian Zhi Hu; Donald N Rommereim; Mark K Murphy; Richard P Phipps; David L Huso; John F Dicello
Journal:  Radiat Res       Date:  2009-11       Impact factor: 2.841

4.  Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.

Authors:  Cristina Nanni; Elena Zamagni; Mohsen Farsad; Paolo Castellucci; Patrizia Tosi; Delia Cangini; Eugenio Salizzoni; Romeo Canini; Michele Cavo; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-02       Impact factor: 9.236

Review 5.  Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer.

Authors:  Michael A Jacobs; Li Pan; Katarzyna J Macura
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

6.  Whole-body magnetic resonance imaging for detecting bone metastases: comparison with bone scintigraphy.

Authors:  G Cascini; C Falcone; C Greco; B Bertucci; S Cipullo; O Tamburrini
Journal:  Radiol Med       Date:  2008-10-25       Impact factor: 3.469

7.  Whole-body MRI and PET-CT in the management of cancer patients.

Authors:  Gerwin P Schmidt; Alexander R Haug; Stefan O Schoenberg; Maximilian F Reiser
Journal:  Eur Radiol       Date:  2006-03-15       Impact factor: 5.315

Review 8.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

9.  [Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging].

Authors:  A Heidenreich; S Krege
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

Review 10.  Whole body MRI and PET/CT in haematological malignancies.

Authors:  Chieh Lin; Alain Luciani; Emmanuel Itti; Corinne Haioun; Alain Rahmouni
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.